您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 7913 处方药 7544 非处方药 253 保健品/医疗用具 116

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 抗病毒药物->抗艾滋病药物
处方药:处方药
包装规格: 40毫克粉剂 60克/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
美国吉利德科学公司
生产厂家英文名:
GILEAD SCIENCES INC
该药品相关信息网址1:
http://www.viread.com/
该药品相关信息网址2:
http://www.viread.com/ch/100.cfm
该药品相关信息网址3:
http://www.aidsmeds.com/archive/Viread_1587.shtml
原产地英文商品名:
VIREAD 40MG ORAL POWDER 60g/bottle
原产地英文药品名:
TENOFOVIR DISOPROXIL FUMARATE
中文参考商品译名:
VIREAD 40毫克粉剂 60克/瓶
中文参考药品译名:
替诺福韦酯富马酸盐
原产地国家批准上市年份:
2012/01/18
英文适应病症1:
HIV-1
英文适应病症2:
chronic hepatitis B
临床试验期:
完成
中文适应病症参考翻译1:
艾滋病-1
中文适应病症参考翻译2:
慢性乙肝
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2009112423455440.pdf,201252222580830.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

部分中文替诺福韦处方资料(仅供参考)

替诺福韦(Viread)是HIV/HBV复合感染的治疗选择
  在美国第12届逆转录病毒和机会感染会议上,美国学者报告,他们进行的一项有关替诺福韦(tenofovir)与阿德福韦(adefovir)安全性临床对照研究显示,替诺福韦可安全有效地降低HIV感染病人的乙型肝炎病毒(HBV)水平。
  该研究的领导者Peters医师解释说,这是替诺福韦对HIV/HBV复合感染病人治疗有效的首次随机对照研究。他说,在HIV感染者中,有20%的人合并乙型肝炎。
  无论在美国还是在全世界,复合感染都是一个重要问题。
  Peters和AIDS临床试验组A5127的研究人员,对52例应用稳定联合抗逆转录病毒治疗的合并HBV感染的病人进行了研究。基线时,有75%的病人HIVRNA低于50拷贝/mL,98%有代偿性肝病。
  这些病人随机进入替诺福韦300 mg/d+安慰剂组,或阿德福韦10mg/d+安慰剂组,疗程96周。每周进行实验室评估。有80%的病人服用过拉米夫定。
  结果显示,替诺福韦对野生型和拉米夫定抗药型HBV均有治疗活性。Peters说,替诺福韦曾被批准用于治疗HIV感染,但非HBV感染。阿德福韦最近被允许用于HBV感染。
  分析表明,替诺福韦的疗效不亚于阿德福韦。替诺福韦降低HBVDNA的效果实际上优于阿德福韦。48周后,替诺福韦组病人的HBV DNA平均log10倍加权平均值较基线时降低4.4,阿德福韦组降低3.21。
  两组均有18例病人的实验室指标异常;均无不良事件发生。虽然两组均有2例死亡,但与治疗用药无关;未发现有肾毒性。
  Peters总结认为,替诺福韦是HIV/HBV复合感染病人的治疗选择。虽然曾有非对照试验资料,但这是证明疗效的首次随机对照研究,它为HIV/HBV感染病人增加了新的治疗选择。
 美国抗HIV药Viread将申报抗肝炎适应症
美国生物制药公司Gilead Sciences(Nasdaq: GILD)于2007年6月25日对外公布说,新的III期临床研究再次证实其抗HIV药Viread对丙型肝炎病毒有疗效。Viread是非核酸类反转录酶抑制剂,2006年获批在美国和欧洲上市。Gilead在今年6月完成了2个III期临床研究,分别针对两种不同亚型的乙型肝炎病毒,都得到了阳性结果。Gilead将于今年第四季度完成在美国和欧洲以乙型肝炎为扩大适应症的上市申请。
 Gilead公司3月8日宣布,美国FDA已授予其抗逆转录病毒药物Viread(替诺福韦)和Truvada(恩曲他滨/替诺福韦)传统批准地位。Truvada含有该公司两种抗逆转录药Emtriva(恩曲他滨)和Viread。

VIREAD works by interfering with the normal working of an enzyme (HBV DNA polymerase) that is essential for the hepatitis B virus (HBV) to reproduce itself. VIREAD may help lower the amount of hepatitis B virus in your body by lowering the ability of the virus to multiply and infect new liver cells.1
VIREAD has also been used since 2001 as a treatment for Human Immunodeficiency Virus (HIV) infection in adults age 18 years and older. VIREAD is always used in combination with other anti-HIV-1 medicines to treat people with HIV-1 infection.1
1 INDICATIONS AND USAGE
1.1 HIV-1 Infection
VIREAOCI is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
The following points should be considered when initiating therapy with VIREAO for the treatment of HIV-1 infection:
· VIREAO should not be used in combination with RUVAOACI or ATRIPLACI ).
1.2 Chronic Hepatitis B
VIREAO is indicated for the treatment of chronic hepatitis B in adults. The following points should be considered when initiating therapy with VIREAO for the treatment of HBV infection:
. This indication is based primarily on data from treatment of nucleoside-treatment-naïve subjects and a smaller number of subjects who had previously received lamivudine or adefovir. Subjects were adults with HBeAg-positive and HBeAg
negative chronic hepatitis B with compensated liver disease
. The numbers of subjects in clinical trials who had lamivudine- or adefovirassociated substitutions at baseline were too small to reach conclusions of efficacy , Clinical Effcacy in Patients with Chronic Hepatitis B。
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
For the treatment of HIV-1 or chronic hepatitis B: The dose of VIREAD is 300 mg once daily taken orally, without regard to food. In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown.
2.2 Dose Adjustment for Renal Impairment
Significantly increased drug exposures occurred when VIREAD was administered to subjects with moderate to severe renal impairment 。
Therefore, the dosing interval of VIREAD should be adjusted in patients with baseline creatinine clearance ..50 mL/min using the recommendations in Table 1. These dosing interval recommendations are based on modeling of single-dose pharmacokinetic data in non-HIV and non-HBV infected subjects with varying degrees of renal impairment,
including end-stage renal disease requiring hemodialysis. The safety and effectiveness of these dosing interval adjustment recommendations have not been clinically evaluated
in patients with moderate or severe renal impairment, therefore clinical response to treatment and renal function should be closely monitored in these patients .
No dose adjustment is necessary for patients with mild renal impairment (creatinine clearance 50-80 mL/min). Routine monitoring of calculated creatinine clearance and
serum phosphorus should be performed in patients with mild renal impairment ) .

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2009112423455440.pdf,201252222580830.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2018-07-31
附件:
201252222580830.pdf    



2009112423455440.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com